HIV latency in the humanized BLT mouse

Journal of Virology

Volumn 86, Issue 1, 2012, Pages 339-347

  Marsden, Matthew D ^a   Kovochich, Michael ^a   Suree, Nuttee ^b   Shimizu, Saki ^b   Mehta, Roshni ^a   Cortado, Ruth ^b   Bristol, Gregory ^a   An, Dong Sung ^b   Zackc, Jerome A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 DEOXYPHORBOL 13 PHENYLACETATE; DIDANOSINE; GAG PROTEIN; INDINAVIR; PHENYLACETIC ACID DERIVATIVE; PROSTRATIN; PROTEIN KINASE C ACTIVATOR; RALTEGRAVIR; SAQUINAVIR; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CD4 CD8 RATIO; CONCENTRATION RESPONSE; CONTROLLED STUDY; EX VIVO STUDY; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LATENT VIRUS INFECTION; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; SPLEEN CELL; THYMUS; UPREGULATION; VIRUS ACTIVATION; VIRUS DETECTION; VIRUS DNA CELL DNA INTERACTION; VIRUS INDUCTION; VIRUS LATENCY; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; BONE MARROW; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HIV; HIV INFECTIONS; HUMANS; LIVER; MICE; MICE, SCID; THYMUS GLAND; VIRAL LOAD; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84855982473     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06366-11     Document Type: Article

References (46)

1. Adachi A, et al. 1986. Production of acquired immunodeciency syndrome-associated retrovirus in human and nonhuman cells trans-fected with an infectious molecular clone. J. Virol. 59:284-291.
2. Amado RG, Jamieson BD, Cortado R, Cole SW, Zack JA. 1999. Recon-stitution of human thymic implants is limited by human immunode-ciency virus breakthrough during antiretroviral therapy. J. Virol. 73: 6361-6369.
3. Arlen PA, et al. 2006. Rapid expression of human immunodeciency virus following activation of latently infected cells. J. Virol. 80:1599-1603.
4. Berges BK, Akkina SR, Remling L, Akkina R. 2010. Humanized Rag2(-/-) gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year. Virology 397:100-103.
5. Bocklandt S, Blumberg PM, Hamer DH. 2003. Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate. Antiviral Res. 59:89-98.
6. Bosque A, Planelles V. 2009. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 113:58-65.
7. Bristol GC, Gao LY, Zack JA. 1997. Preparation and maintenance of SCID-hu mice for HIV research. Methods (San Diego, Calif.) 12: 343-347.
8. Brooks DG, Arlen PA, Gao L, Kitchen CM, Zack JA. 2003. Identication of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc. Natl. Acad. Sci. U. S. A. 100:12955-12960.
9. Brooks DG, et al. 2003. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 19:413-423.
10. Brooks DG, Kitchen SG, Kitchen CM, Scripture-Adams DD, Zack JA. 2001. Generation of HIV latency during thymopoiesis. Nat. Med. 7:459-464.
11. Brooks DG, Zack JA. 2002. Effect of latent human immunodeciency virus infection on cell surface phenotype. J. Virol. 76:1673-1681.
12. Burke B, et al. 2007. Primary cell model for activation-inducible human immunodeciency virus. J. Virol. 81:7424-7434.
13. Chun T-W, Davey RT, Engel D, Lane HC, Fauci AS. 1999. AIDS: re-emergence of HIV after stopping therapy. Nature 401:874-875.
14. Chun TW, et al. 1997. Quantication of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188.
15. Chun TW, et al. 1998. Early establishment of a pool of latently infected, resting CD4(+) T cells during primaryHIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 95:8869-8873.
16. Chun TW, et al. 1999. Effect of interleukin-2 on the pool of latently infected, resting CD4+T cells inHIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 5:651-655.
17. Chun TW, et al. 1995. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med. 1:1284-1290.
18. Denton PW, et al. 2008. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5:e16.
19. Denton PW, et al. 2010. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in hu-manized BLT mice. PLoS One 5:e8829.
20. Dinoso JB, et al. 2009. Treatment intensication does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 106:9403-9408.
21. Finzi D, et al. 1999. Latent infection of CD4+ T cells provides a mecha-nism for lifelong persistence of HIV-1, even in patients on effective com-bination therapy. Nat. Med. 5:512-517.
22. Finzi D, et al. 1997. Identication of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
23. Gulick RM, et al. 1997. Treatment with indinavir, zidovudine, and lami-vudine in adults with human immunodeciency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
24. Hammer SM, et al. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeciency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337:725-733.
25. Jamieson BD, Zack JA. 1998. In vivo pathogenesis of a human immuno-deciency virus type 1 reporter virus. J. Virol. 72:6520-6526.
26. Joseph A, et al. 2008. Lentiviral vectors encoding human immunode-ciency virus type 1 (HIV-1)-specic T-cell receptor genes efciently con-vert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivoHIV-1-specic inhibitory activity. J. Virol. 82:3078-3089.
27. Korin YD, Brooks DG, Brown S, Korotzer A, Zack JA. 2002. Effects of prostratin on T-cell activation and human immunodeciency virus latency. J. Virol. 76:8118-8123.
28. Kovochich M, Marsden MD, Zack JA. 2011. Activation of latent HIV using drug-loaded nanoparticles. PLoS One 6:e18270.
29. Kulkosky J, et al. 2001. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98: 3006-3015.
30. Kulkosky J, et al. 2002. Intensication and stimulation therapy for human immunodeciency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J. Infect. Dis. 186:1403-1411.
31. Marsden MD, Zack JA. 2009. Eradication of HIV: current challenges and new directions. J. Antimicrob. Chemother. 63:7-10.
32. Marsden MD, Zack JA. 2010. Establishment and maintenance of HIV latency: model systems and opportunities for intervention. Future Virol. 5:97-109.
33. McCune JM, et al. 1988. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241:1632-1639.
34. Melkus MW, et al. 2006. Humanized mice mount specic adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 12: 1316-1322.
35. Namikawa R, Weilbaecher KN, Kaneshima H, Yee EJ, McCune JM. 1990. Long-term human hematopoiesis in the SCID-hu mouse. J. Exp. Med. 172:1055-1063.
36. Prins JM, et al. 1999. Immuno-activation with anti-CD3 and recombinant human IL-2 inHIV-1-infected patients on potent antiretroviral therapy. AIDS 13:2405-2410.
37. Scripture-Adams DD, Brooks DG, Korin YD, Zack JA. 2002. Interleukin-7 induces expression of latent human immunodeciency virus type 1 with minimal effects on T-cell phenotype. J. Virol. 76: 13077-13082.
38. Shimizu S, et al. 2010. A highly efcient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 115:1534-1544.
39. Stoddart CA, et al. 2011. Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD-scid IL-2Rgamma(-/-) (NSG) BLT mice. Virology 417:154-160.
40. Traggiai E, et al. 2004.Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304:104-107.
41. Wender PA, Kee JM, Warrington JM. 2008. Practical synthesis of pros-tratin, DPP, and their analogs, adjuvant leads against latent HIV. Science 320:649-652.
42. Withers-Ward ES, et al. 1997. Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy. Nat. Med. 3:1102-1109.
43. Wong JK, et al. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
44. Yang HC, et al. 2009. Small-molecule screening using a human primary cellmodel of HIV latency identies compounds that reverse latency with out cellular activation. J. Clin. Invest. 119:3473-3486.
45. Yu D, Wang W, Yoder A, Spear M, Wu Y. 2009. The HIV envelope bu not VSV glycoprotein is capable of mediating HIV latent infection of rest ing CD4 T cells. PLoS Pathog. 5:e1000633.
46. Zack JA, et al. 1990. HIV-1 entry into quiescent primary lymphocytes: mo lecular analysis reveals a labile, latent viral structure. Cell 61:213-222.